Literature DB >> 11197361

Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy.

H Liu, A Ruskon-Fourmestraux, A Lavergne-Slove, H Ye, T Molina, Y Bouhnik, R A Hamoudi, T C Diss, A Dogan, F Megraud, J C Rambaud, M Q Du, P G Isaacson.   

Abstract

20-30% of gastric mucosa-associated lymphoid tissue (MALT) lymphoma associated with Helicobacter pylori do not regress after antibiotic therapy. Regression can be assessed only by extended follow-up. To assess whether t(11;18, q21;q21), which results in a chimeric transcript between the AP12 and MLT genes, predicts lymphoma resistance to antibiotic therapy, we screened for the fusion transcript with RT-PCR in ten responsive and 12 non-responsive gastric MALT lymphomas. The AP12-MLT transcript was detected in nine (75%) of 12 patients non-responsive to antibiotic therapy but not in responsive patients. Most H pylori-associated gastric MALT lymphomas that do not respond to antibiotic therapy are associated with t(11;18, q21;q21).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11197361     DOI: 10.1016/S0140-6736(00)03571-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  73 in total

Review 1.  Therapy of non-Hodgkin's lymphoma.

Authors:  J Coffey; D C Hodgson; M K Gospodarowicz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-12       Impact factor: 9.236

2.  Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas.

Authors:  K Völp; M-L Brezniceanu; S Bösser; T Brabletz; T Kirchner; D Göttel; S Joos; M Zörnig
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

Review 3.  Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management.

Authors:  M-Q Du; J C Atherton
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

4.  H. pylori negative MALT lymphoma patients successfully treated with antibiotics: doubts about their H. pylori negativity.

Authors:  E Lahner; M Milione; G Delle Fave; B Annibale
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

5.  Primary extranodal lymphomas of gastrointestinal localizations: a single institution 5-yr experience.

Authors:  B Mihaljević; R Nedeljkov-Jancić; V Vujicić; D Antić; S Janković; N Colović
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

6.  Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series.

Authors:  W Fischbach; M-E Goebeler-Kolve; B Dragosics; A Greiner; M Stolte
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

Review 7.  The classification of lymphomas: a new beginning or the end of an era?

Authors:  A S Jack
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

Review 8.  Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas.

Authors:  Richard J Bende; Febe van Maldegem; Carel J M van Noesel
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

Review 9.  Molecular diagnosis in lymphoma.

Authors:  Adam Bagg
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

Review 10.  Treatment of gastric MALT lymphoma with a focus on Helicobacter pylori eradication.

Authors:  Qing Guo; Shanqi Guo; Yizhuo Zhang
Journal:  Int J Hematol       Date:  2013-04-25       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.